Taro-Testosterone Cypionate Injection is an injectable testosterone product used to treat men with low testosterone (hypogonadism). It may also be used off-label in gender-affirming hormone therapy for transgender men and some nonbinary individuals, as well as in select cases for women. It is given by injection and releases testosterone gradually into the body over time.
Taro-Testosterone Cypionate Injection is a generic version of Pfizer’s former Depo-Testosterone, which was withdrawn from the Canadian market in October 2025.
In Canada, testosterone cypionate is one of only two injectable testosterone products. It is available as a 100 mg/mL solution in a multi-dose vial. Because it is less concentrated than testosterone enanthate (200 mg/mL), each dose requires twice the injection volume for the same amount of testosterone. This can affect comfort for some patients, particularly with long-term use.
Taro-Testosterone Cypionate Injection is formulated in cottonseed oil. This matters for people with allergies or sensitivities, especially compared with testosterone enanthate products, which are typically made with sesame oil. Some patients find they tolerate one better than the other.
Injectable testosterone is often preferred by patients who want to avoid daily treatments like gels or nasal products. However, depending on the dosing schedule, testosterone levels can rise and fall more noticeably between doses.
Like all testosterone products, this medication is used on an ongoing basis. If shortages occur, switching to another product may be necessary. Because different formulations (such as gels or other injectables) behave differently in the body, dose adjustments and monitoring are usually required when changing treatments.
Because there are only two injectable options in Canada, shortages of either product can quickly affect availability nationwide.
Public Coverage
Taro-Testosterone Cypionate Injection is listed on many provincial and territorial public drug plans in Canada, but coverage depends on clinical criteria, prior authorization, and individual eligibility.
We don’t collect your email. This uses a third-party service to notify you when this page changes.